Skip to main content

Table 2 Clinical data and demographics corresponding to CSF samples from subjects with or without G2019S-LRRK2 mutations, with or without PD

From: Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers

  LRRK2+/PD- LRRK2+/PD+ LRRK2-/PD+ LRRK2-/PD- p valuea
Gender M(F) 13(26) 3(16) 11(8) 0(5) 0.008
Age 63 (56-69) 57 (53-69) 60 (50-67) 60 (44.5-74) ns
Age at onset NA 55 (47-65) 57 (50-60) NA ns
LEDD NA 600 (250-675) 300 (0-550) NA ns
UPDRS_III 5 (0-6) 18 (15-22) 20 (16.25-22) 0 (0-0) <0.0001
MoCA 26 (26-28) 26 (25-27) 27 (26-28) 27 (<26-30) ns
H&Y 0 (0-0) 2 (2-2.5) 2 (2-2) 0 (0-0) <0.0001
  1. LEDD is L-dopa equivalent daily dosage, UPDRS is Unified Parkinson’s Disease Rating Scale, MoCA is Montreal Cognitive Assessment, H&Y is Hoehn & Yahr scale, NA is not applicable; Values reported are group median (interquartile range). aDetermined by comparing LRRK2+/PD- to LRRK2+/PD+ using the Dunn post hoc test following Kruskal-Wallis test of all groups. ns is not significant as determined by Pearson chi square (MoCA), ANOVA (age at test), t test (age at onset), Mann-Whitney test (LEDD) and Kruskal-Wallis test (H&Y, UPDRS III)